Please type a plus sign (+) inside this box \longrightarrow	F	-
---	---	---

				Complete if Known		
Substitute for fo	rm 1449A/B/PTO			Application Number	10/802,220	
INFORMATION DISCLOSURE				Filing Date	March 17, 2004	
	TEMENT BY			First Named Inventor	Uemoto	
SIA	IEMENIBI	AP	PLICANI	Group Art Unit	1628	
(Use as many sheets as necessary)				Examiner Name	Pagonakis, A.	
Sheet	1	of	1	Attorney Docket Number	227833	

U.S. PATENT DOCUMENTS							
		U.S. Patent Do	cument				
Examiner Initials	Doc. No.	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate	
						1	
					+		
			1				
						-	
	-		1				
			1				
			_				

	FOREIGN PATENT DOCUMENTS								
		F	oreign Patent Docume	nt					
Examiner Initials	Doc. No.	Office	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Translation *		
/A.P./	GC	WO	2003/000226	A2	Pfizer Products Inc.	Jan. 3, 2003			
/A.P./	GD	wo	2003/000238	A1	Pfizer Products Inc.	Jan. 3, 2003			
/A.P./	GE	wo	2003/063831	A2	Pfizer Products Inc.	Aug. 7, 2003			
/A.P./	GF	wo	2003/063868	A1	Pfizer Products Inc.	Aug. 7, 2003			

		OTHER - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation *
/A.P./	GG	BASF Aktiengesellschaft Kollidon® Product Brochure, "Polyvinylpyrrolidone for the pharmaceutical industry," 6 th Corrected Edition (April 2002)	

Examiner Signature	/Anna Pagonakis/	Date Considered	10/11/2011				
* If the reference is not in English, then at least one of the following is provided: (a) an English translation in whole or in part or (b) a concise statement							

If the reterence is not in English, then at least one of the following is provided; (a) an English translation in whole or in part or (b) a concise statement of relevance in the form of, for example, an English language counterpart, an English-language abstract, or an English-language version of the search report or action by a foreign partent office in a counterpart foreign application indicating the degree of relevance found by the foreign office.